Dr. Varun V. Monga, MD | Iowa City, IA ...

Dr. Varun Monga, MD

Claim this profile

University of Iowa Hospitals and Clinics

Studies Soft Tissue Sarcoma
Studies Cancer
17 reported clinical trials
26 drugs studied

Area of expertise

1Soft Tissue Sarcoma
Varun Monga, MD has run 7 trials for Soft Tissue Sarcoma. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Cancer
Varun Monga, MD has run 6 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
NTRK positive

Affiliated Hospitals

Image of trial facility.
University Of Iowa Hospitals And Clinics
Image of trial facility.
University Of Iowa/Holden Comprehensive Cancer Center

Clinical Trials Varun Monga, MD is currently running

Image of trial facility.

Multiple Targeted Therapies

for Meningioma

This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting1 award Phase 210 criteria
Image of trial facility.

Immunotherapy + Chemotherapy

for Sarcoma

This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). Doxorubicin is in a class of medications called anthracyclines. Doxorubicin damages the cell's deoxyribonucleic acid (DNA) and may kill tumor cells. It also blocks a certain enzyme needed for cell division and DNA repair. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding immunotherapy (pembrolizumab) to the standard chemotherapy (doxorubicin) may help patients with metastatic or unresectable DDLPS, UPS or a related poorly differentiated sarcoma live longer without having disease progression.
Recruiting2 awards Phase 310 criteria

More about Varun Monga, MD

Clinical Trial Related1 year of experience running clinical trials · Led 17 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Varun Monga, MD has experience with
  • Temozolomide
  • Abemaciclib
  • Radiotherapy
  • Ascorbate
  • Radiation Therapy
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Varun Monga, MD specialize in?
Is Varun Monga, MD currently recruiting for clinical trials?
Are there any treatments that Varun Monga, MD has studied deeply?
What is the best way to schedule an appointment with Varun Monga, MD?
What is the office address of Varun Monga, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security